Chemistry:Non-racemic MDMA
-MDMA.svg) | |
-MDMA.svg) (R)-MDMA (top) and (S)-MDMA (bottom) | |
| Combination of | |
|---|---|
| (R)-MDMA | Entactogen; Serotonin–norepinephrine releasing agent (SNRA) |
| (S)-MDMA | Entactogen; Serotonin–norepinephrine–dopamine releasing agent (SNDRA) |
| Clinical data | |
| Other names | Non-racemic midomafetamine; Non-racemic ecstasy; ALA-002; ALA002; ALA-02; ALA02; AM-1002; AM1002 |
Non-racemic MDMA, also known by the developmental code names ALA-002 and AM-1002, are non-racemic mixtures of the MDMA (midomafetamine; "ecstasy") enantiomers (R)-MDMA and (S)-MDMA which are under development for the treatment of social phobia (social anxiety disorder; SAD), autistic spectrum disorder (ASD), and generalized anxiety disorder (GAD).[1][2][3] ALA-002, which is under development by PharmAla Biotech for social phobia and autistic spectrum disorders, is a mixture of 70–80% (R)-MDMA and 20–30% (S)-MDMA.[1][4] Conversely, AM-1002, which is under development by Arcadia Medicine for GAD, is a mixture of 90% (R)-MDMA and 10% (S)-MDMA.[5] Based on animal studies, (R)-MDMA-preferring non-racemic MDMA mixtures show less hyperlocomotion, hyperthermia, hypertension, and neurotoxicity than racemic MDMA.[5][6] ALA-002 is in phase 2 clinical trials for SAD and ASD as of 2026, whereas AM-1002 is in phase 1/2 trials for GAD as of 2026.[1][2][7] Jupiter Neurosciences acquired the exclusive rights to develop ALA-002 in the United States from PharmAla Biotech in May 2026.[8]
See also
- List of investigational hallucinogens and entactogens
- List of investigational social anxiety disorder drugs
- List of investigational autism and pervasive developmental disorder drugs
- List of investigational generalized anxiety disorder drugs
- (R)-MDMA (EMP-01, DT402/MM402)
- APA-01 (APA-001; PharmAla-1)
References
- ↑ 1.0 1.1 1.2 "ALA 002". 19 December 2025. https://adisinsight.springer.com/drugs/800070800.
- ↑ 2.0 2.1 "AM 1002". 16 October 2025. https://adisinsight.springer.com/drugs/800084874.
- ↑ "Psychedelics Coming into the Modern Age of Medicine: The history of psychedelics spans the spiritual, the recreational, and the legal—and now the medical, thanks to safer and more convenient molecules and protocols". Genetic Engineering & Biotechnology News 44 (2): 44–47. 1 February 2024. doi:10.1089/gen.44.02.15. ISSN 1935-472X. "In animal studies, PharmAla Biotech has demonstrated that its molecule, ALA-002, does not result in a rise in body temperature or blood pressure. ALA002 also has a much lower abuse potential than generic MDMA. A Phase II trial will begin in 2024 to treat social anxiety in autistic adults.".
- ↑ "Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark OfficeNovel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities". 27 March 2024. https://www.biospace.com/patent-allowance-granted-for-ala-002-composition-by-us-patent-and-trademark-officenovel-composition-of-mdma-enantiomers-leading-to-next-generation-mdma-possibilities.
- ↑ 5.0 5.1 "Patented formulation of MDMA receives federal "Investigational New Drug" status; Intravenous ketamine outperforms esketamine". 10 October 2025. https://themicrodose.substack.com/p/patented-formulation-of-mdma-receives. "MDMA is what is called a “racemic mixture”: it contains an equal proportion of two molecular structures, known as R-MDMA and S-MDMA, which are mirror images of each other. Arcadia’s AM-1002 is a non-racemic MDMA; according to its patent application for the drug, it contains a mix of nine parts R-MDMA to one part S-MDMA. Previous research has suggested that while S-MDMA is associated with strong visual effects and higher blood pressure, R-MDMA provides more stimulation of serotonin receptors. The company calls its drug a “non-neurotoxic form of MDMA with an improved therapeutic profile,” and plans to start a clinical trial investigating its use in treating generalized anxiety disorder."
- ↑ "Thermoregulatory and locomotor effects of 3,4-methylenedioxy-methamphetamine (MDMA), its enantiomers, and a non-racemic mixture [of S-MDMA and R-MDMA (ALA-002) in C57BL/6 and BTBR T + Itpr3 tf /J mice"]. 15th Annual Behavior, Biology and Chemistry (BBC): Translational Research in Substance Use Disorders. 2023. https://pharmala.ca/assets-documents/Poster_Presentation_3.pdf.
- ↑ "Psychedelic Drug Development Tracker". https://psychedelicalpha.com/resources/psychedelic-drug-development-tracker/.
- ↑ "PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million". 20 May 2026. https://www.biospace.com/press-releases/pharmala-biotech-signs-term-sheet-to-license-exclusive-u-s-rights-to-ala-002-its-next-generation-mdma-therapeutic-to-jupiter-neurosciences-inc-nasdaq-juns-in-a-transaction-valued-at-over-100-million.
 |  |
